Published in J Rheumatol on August 01, 2013
Smoking, Porphyromonas gingivalis and the immune response to citrullinated autoantigens before the clinical onset of rheumatoid arthritis in a Southern European nested case-control study. BMC Musculoskelet Disord (2015) 1.45
Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nat Rev Rheumatol (2014) 1.39
The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Semin Immunopathol (2014) 0.95
Strategies to predict rheumatoid arthritis development in at-risk populations. Rheumatology (Oxford) (2014) 0.82
Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans. Arthritis Res Ther (2016) 0.78
Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases. Clin Rheumatol (2015) 0.77
Characterization of Autoantigens Targeted by Anti-Citrullinated Protein Antibodies In Vivo: Prominent Role for Epitopes Derived from Histone 4 Proteins. PLoS One (2016) 0.75
Perceptions of risk and predictive testing held by the first-degree relatives of patients with rheumatoid arthritis in England, Austria and Germany: a qualitative study. BMJ Open (2016) 0.75
Systematic review of rheumatic disease phenotypes and outcomes in the Indigenous populations of Canada, the USA, Australia and New Zealand. Rheumatol Int (2016) 0.75
Meta-analysis: diagnostic accuracy of antibody against peptidylarginine deiminase 4 by ELISA for rheumatoid arthritis. Clin Rheumatol (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum (2003) 10.65
Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum (2004) 7.79
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet (2003) 7.04
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet (2005) 6.61
Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum (2004) 3.38
Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum (2010) 2.53
Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum (2007) 2.40
Duration of preclinical rheumatoid arthritis-related autoantibody positivity increases in subjects with older age at time of disease diagnosis. Ann Rheum Dis (2007) 2.38
Arthritis in Aboriginal Manitobans: evidence for a high burden of disease. J Rheumatol (2008) 2.31
N-α-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 2.18
Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One (2012) 2.18
Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med (2010) 1.78
Familial associations of rheumatoid arthritis with autoimmune diseases and related conditions. Arthritis Rheum (2009) 1.73
Association between PADI4 and rheumatoid arthritis: a replication study. Arthritis Rheum (2005) 1.52
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann Rheum Dis (2011) 1.45
Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes. J Rheumatol (2005) 1.44
Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. Arthritis Rheum (2011) 1.39
Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum (2008) 1.35
Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Rheumatoid arthritis in American Indians and Alaska Natives: a review of the literature. Semin Arthritis Rheum (2005) 1.23
Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis (2007) 1.15
Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum (2012) 1.09
Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. Ann Rheum Dis (2008) 1.08
Rheumatoid arthritis-specific autoantibodies to peptidyl arginine deiminase type 4 inhibit citrullination of fibrinogen. Arthritis Rheum (2010) 1.07
Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol (2008) 1.07
Bacterial and human peptidylarginine deiminases: targets for inhibiting the autoimmune response in rheumatoid arthritis? Arthritis Res Ther (2010) 1.03
Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol (2005) 1.02
Immunogenetic risks of anti-cyclical citrullinated peptide antibodies in a North American Native population with rheumatoid arthritis and their first-degree relatives. J Rheumatol (2009) 1.01
Rheumatoid arthritis in Tlingit Indians: clinical characterization and HLA associations. J Rheumatol (1994) 0.87
Predominance of IgG1 and IgG3 subclasses of autoantibodies to peptidylarginine deiminase 4 in rheumatoid arthritis. Clin Rheumatol (2011) 0.85
Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: a reflection of the involvement of transglutaminase in coeliac disease. Eur J Intern Med (2009) 0.78
Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol (2005) 9.25
Monodisperse MFe2O4 (M = Fe, Co, Mn) nanoparticles. J Am Chem Soc (2004) 5.97
Disruption of GW bodies impairs mammalian RNA interference. Nat Cell Biol (2005) 5.52
A phosphorylated cytoplasmic autoantigen, GW182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell (2002) 5.34
The GW182 protein colocalizes with mRNA degradation associated proteins hDcp1 and hLSm4 in cytoplasmic GW bodies. RNA (2003) 4.40
International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis (2013) 3.99
GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation. J Cell Sci (2004) 3.31
Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum (2004) 3.23
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum (2011) 2.99
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med (2005) 2.82
Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci Transl Med (2013) 2.51
Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci Transl Med (2013) 2.51
Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science (2013) 2.46
Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol (2012) 2.43
B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum (2009) 2.26
Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives. J Rheumatol (2010) 2.21
Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol (2014) 1.99
Oxidation in rheumatoid arthritis. Arthritis Res Ther (2004) 1.96
Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep (2006) 1.92
Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem (2002) 1.88
Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum (2004) 1.87
Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis (2009) 1.84
Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. Mol Biol Cell (2007) 1.83
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol (2011) 1.80
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol (2010) 1.73
The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 and requires GW182 to mediate silencing. RNA (2009) 1.69
The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A (2005) 1.69
Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum (2005) 1.67
The role of GW/P-bodies in RNA processing and silencing. J Cell Sci (2007) 1.63
Anti-NMDA receptor encephalitis. The disorder, the diagnosis and the immunobiology. Autoimmun Rev (2012) 1.60
Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum (2010) 1.54
Apoptotic cell blebs: repositories of autoantigens and contributors to immune context. Arthritis Rheum (2009) 1.53
Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. J Cell Sci (2008) 1.53
Recognition of Granzyme B-generated autoantigen fragments in scleroderma patients with ischemic digital loss. Arthritis Rheum (2002) 1.53
Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther (2010) 1.50
Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum (2008) 1.48
Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther (2008) 1.47
Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann Rheum Dis (2011) 1.45
First-degree relatives of patients with rheumatoid arthritis exhibit high prevalence of joint symptoms. J Rheumatol (2013) 1.44
Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes. J Rheumatol (2005) 1.44
Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther (2007) 1.40
Autocitrullination of human peptidyl arginine deiminase type 4 regulates protein citrullination during cell activation. Arthritis Rheum (2010) 1.39
Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum (2008) 1.35
A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol (2004) 1.33
Autoimmune targeting of key components of RNA interference. Arthritis Res Ther (2006) 1.32
Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat Clin Pract Rheumatol (2008) 1.32
A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit (2004) 1.31
Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum (2009) 1.31
Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum (2013) 1.27
Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem (2004) 1.26
Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr Opin Rheumatol (2011) 1.26
Apoptosis and autoimmunity. Curr Opin Immunol (2005) 1.25
Clinical and serological associations of autoantibodies to GW bodies and a novel cytoplasmic autoantigen GW182. J Mol Med (Berl) (2003) 1.25
Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum (2010) 1.23
Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. J Immunol Methods (2006) 1.20
Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev (2011) 1.19
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J (2006) 1.19
Interferon-alpha regulates the dynamic balance between human activated regulatory and effector T cells: implications for antiviral and autoimmune responses. Immunology (2010) 1.18
Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci (2010) 1.17
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum (2007) 1.17
The development of systemic sclerosis classification criteria. Clin Rheumatol (2007) 1.17
The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol (2012) 1.15
Primary ciliogenesis defects are associated with human astrocytoma/glioblastoma cells. BMC Cancer (2009) 1.13
Comparison between multiplex assays for autoantibody detection in systemic lupus erythematosus. J Immunol Methods (2010) 1.13
Fragmentation of Golgi complex and Golgi autoantigens during apoptosis and necrosis. Arthritis Res (2002) 1.12
Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol (2003) 1.11
Clinical phenotypes of patients with anti-DFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol (2013) 1.11
Precise probes of type II interferon activity define the origin of interferon signatures in target tissues in rheumatic diseases. Proc Natl Acad Sci U S A (2012) 1.10
A panel of monoclonal antibodies to cytoplasmic GW bodies and the mRNA binding protein GW182. Hybrid Hybridomics (2003) 1.09
Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum (2012) 1.09
Altered structure of autoantigens during apoptosis. Rheum Dis Clin North Am (2004) 1.09
Granzyme H destroys the function of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. EMBO J (2007) 1.09
Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther (2004) 1.08
Mouse and human granzyme B have distinct tetrapeptide specificities and abilities to recruit the bid pathway. J Biol Chem (2006) 1.08
Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA. J Rheumatol (2007) 1.08
Insights into the significance of peptidylarginine deiminase 4 and antibodies against citrullinated antigens in the absence of "true ACPAs" in an experimental model of arthritis: comment on the article by Shelef et al. Arthritis Rheumatol (2014) 1.08
Caspase-resistant Golgin-160 disrupts apoptosis induced by secretory pathway stress and ligation of death receptors. Mol Biol Cell (2005) 1.07
Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol (2007) 1.07
Rheumatoid factors: what do they tell us? J Rheumatol (2002) 1.06
Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. Clin Immunol (2004) 1.06
Apoptosis in systemic lupus erythematosus. Curr Opin Rheumatol (2003) 1.05
GW bodies, microRNAs and the cell cycle. Cell Cycle (2006) 1.05
Autoantibodies in systemic sclerosis. Autoimmun Rev (2012) 1.05
The antinuclear antibody test: last or lasting gasp? Arthritis Rheum (2011) 1.05
Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci U S A (2003) 1.03
Cytoplasmic ribonucleoprotein (RNP) bodies and their relationship to GW/P bodies. Int J Biochem Cell Biol (2009) 1.03